On Friday, Shares of AT&T Inc. (NYSE:T), SUBTRACT -0.29% and closed at $40.61 in the last trading session. The last trading range of the stock ranges between $40.60 and $41.04. AT&T* is giving global businesses the improved flexibility and raised network control they need with AT&T FlexWare. We are now growing the solution with a new device option, improved feature functionality and expanded global availability. AT&T FlexWare, formerly called AT&T Network Functions on Demand, is available globally through the AT&T Network on Demand platform.
With AT&T FlexWare, business customers can set up multiple virtual network functions (VNFs), such as a router and a firewall, on a single FlexWare device and deploy them in different countries. They can manage their network functions via an easy-to-use online portal. It can assist save costs. It’s quick to set up and easy to manage.
“AT&T FlexWare offers businesses flexible networking options,” said Roman Pacewicz, senior vice president, Offer Administration and Service Integration, AT&T Business Solutions. “One size fits all doesn’t allow businesses to compete. Our software-centric ecosystem allows businesses to start with one set of network functions and add as they go. We’re empowering businesses to control and change their services to match their needs across the world.”
Our ecosystem of virtualized applications and devices can be tailored to businesses of all sizes. For example, AT&T FlexWare now offers two device form factors, a small device that can run up to two VNF applications and the formerly available larger version that runs up to four.
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), DROPPED -42.58% and closed at $0.678 in the last trading session. The last trading range of the stock ranges between $0.50 and $0.69. The company’s Market capitalization is $27.82 Million with the total Outstanding Shares of 71.59 Million. Threshold Pharmaceuticals, Inc. (THLD), a clinical-stage biopharmaceutical company specializing in the development of novel pharmaceutical products and technologies for the treatment of cancer, recently declared interim data from its two Phase 2 proof-of-concept clinical trials of tarloxotinib and outlined its plans to focus company resources on the more clinically-advanced evofosfamide program in addition to an earlier-stage anticancer candidate, TH-3424.
“While the response observed in our squamous cell carcinoma of the skin study with tarloxotinib was encouraging, the overall results from the two studies didn’t meet the activity thresholds required to move forward the molecule forward despite the promising results seen in preclinical translational studies,” said Barry Selick, Ph.D., Chief Executive Officer of Threshold. “As a result, we are making no further investment in this program. Instead, we plan to build on the efforts of our collaborator, Dr. Michael Curran of The University of Texas MD Anderson Cancer Center, to demonstrate the potential therapeutic value of adding evofosfamide to immune checkpoint inhibition, to continue to pursue negotiations with Japanese regulatory authorities regarding potential registration pathways for evofosfamide, and to advance TH-3424 through IND-enabling toxicology studies with the aim of reaching the clinic in 2017. We plan to provide additional operational guidance in the fourth quarter of 2016.”